MedTrace Logo

Validation of the French Version of the New Mobility Score (NMS)

NCT07622095 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-09-03

No results posted yet for this study

Summary

The incidence of hip fractures in France is 50,000 cases per year among women and 16,000 among men, with a 1-year mortality rate of 20-24%. After a fracture, 10-30% of patients become functionally dependent. The increasing aging of the population and the rise in dependency are likely to worsen the situation of older patients in hospital settings.

Several tools are available to assess functional independence, including the New Mobility Score (NMS), which evaluates mobility through three domains: mobility indoors, mobility outdoors, and shopping activities. The NMS has shown good performance in predicting patient mortality and functional recovery, and its use is recommended in clinical practice. However, the French version of the NMS has not yet been validated.

The French validation of the NMS is important to facilitate its implementation in clinical practice and research, particularly because of its simplicity and the need for rapid assessment tools for healthcare professionals. A French version of the NMS has been translated, and the MOB-SCORE study aims to assess its reliability and validity among healthcare professionals caring for patients with hip fractures.

Conditions

  • Hip Fractures
  • Mobility Limitation
  • Independence
  • Autonomy

Interventions

OTHER

Questionnaires

New Mobility Score (NMS), Measure of Functional Independence (MIF), Cumulated Ambulation Score (CAS), Mini-Mental State Examination (MMSE).

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-27
Primary Completion
2028-02-29
Completion
2028-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07622095 on ClinicalTrials.gov